Biovest International, Inc.
(Public, OTC:BVTI)
As individuals in our respective societies, we all abide by a certain moral standing. However, regardless of your lifestyle, you will adhere to the notion that there is no greater feeling in the world than knowing you are helping fund a company which could potentially save millions of lives, while at the same time fulfilling your needs through growing your pockets as well. So without further ado, let's all welcome Biovest International, Inc. (OTC:BVTI) as StocksHaven Investment's newest company profile. Recently the company has stricken interest from the investment community through its product, BiovaxID, which has seen very positive Phase III results presented at Asco Plenary Session. BiovaxID is truly revolutionary, the cancer vaccine evokes the power of each patient's immune system and primes it to recognize and eliminate cancerous lymphoma cells, while sparing normal B-cells. Before beginning the analysis, lets also keep in mind that with the phase III were presented nearly four months ago on 05/31/09, meaning an NDA announcement could come at anytime. Biovest's President, Samuel Duffey states, ""We have already initiated discussions with the FDA and EMEA and are preparing for further meetings with those agencies and other international regulatory authorities in order to share our significant results and determine the most appropriate approval regulatory pathways."
About Biovest International Inc.
Biovest International, Inc. (Biovest) is a biotechnology company focusing primarily on the development of BiovaxID, a patient-specific, anti-cancer vaccine focusing on the treatment of follicular non-Hodgkins lymphoma, or follicular NHL. BiovaxID is a customized anti-cancer vaccine that is derived from a patient's own cancer cells and is designed to utilize the power of the patient's immune system to recognize and destroy cancerous lymphoma cells, while sparing normal cells. The Company produces this vaccine by extracting some of the patient's tumor cells and then replicating and purifying the antigen that is present only on the surface of the patient's own tumor cells. Biovest is conducting a pivotal Phase 3 clinical trial for BiovaxID in patients with the indolent, or low-grade, form of B-cell follicular NHL.
Products
BiovaxID Cancer Vaccine
The Biovest cancer immunotherapy stems from work begun in 1986 on development of a patient-specific follicular lymphoma (FL) vaccine. The cancer vaccine evokes the power of each patient's immune system and primes it to recognize and eliminate cancerous lymphoma cells, while sparing normal B-cells. In the vaccine's cancer target, B-cell lymphoma, the process is made possible by the presence of a hallmark surface antigen of the cancer cells that is not present in non-cancerous tissue. By priming the immune system with this antigen in the form of an autologous vaccine, the vaccine induces a powerful immune response against the cancerous cells that in many cases results in pronounced, complete cancer clearance. Because each dose of Biovest's vaccine is derived from individual patient's cancerous cells, the vaccine is a true targeted, customized therapy. The vaccine's powerful anti-tumor effect vastly exceeds that of non-targeted traditional therapy, as it arises from the immune system's defense cells' innate ability to selectively target foreign antigens. Most importantly, the immune response triggered by the vaccine against the cancerous tissue is a natural disease-fighting mechanism and has almost none of the side-effects associated with the broad-spectrum chemotherapy and radiation used to traditionally treat this type of lymphoma.
BiovaxID is individually manufactured from a tissue biopsy obtained from a patient's own tumor, and selectively targets only the cancerous B-cells, while sparing healthy cells. BiovaxID is highly specific in its anti-lymphoma attack because the vaccine "trains" the body's own immune system to recognize as foreign the unique protein (idiotype) expressed only on the cancerous B-cells, thus stimulating and recruiting the patient's own immune system to destroy the cancer cells and potentially prevent recurrence. In contrast, other existing chemotherapeutic and monoclonal antibody therapies destroy most of the healthy B-cells in addition to the cancerous cells, and may result in serious adverse side-effects. Because the BiovaxID vaccine is comprised of the patient's own cells (autologous), the therapy has been demonstrated to be safe and well-tolerated.
Futhermore, as the leading manufacturer of hollow fiber technology and with over 2 decades of cell culture experience, Biovest has pioneered a unique platform to commercialize patient-specific biologics.
